On August 16, 2024, NeuroSense Therapeutics Ltd., a foreign private issuer, announced the entry into a Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC. Under this agreement, NeuroSense may offer and sell ordinary shares with a total value of up to $2,524,437. The sales are to be conducted through an 'at the market offering' as defined by Rule 415 under the Securities Act of 1933, with the possibility of sales on The Nasdaq Capital Market or other trading markets. The offering will be made pursuant to a shelf registration statement and prospectus filed with the SEC in January 2023. NeuroSense is not obligated to sell any shares and the agreement may be terminated by either party or by mutual agreement. The Sales Agent will...Show More

On August 16, 2024, NeuroSense Therapeutics Ltd., a foreign private issuer, announced the entry into a Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC. Under this agreement, NeuroSense may offer and sell ordinary shares with a total value of up to $2,524,437. The sales are to be conducted through an 'at the market offering' as defined by Rule 415 under the Securities Act of 1933, with the possibility of sales on The Nasdaq Capital Market or other trading markets. The offering will be made pursuant to a shelf registration statement and prospectus filed with the SEC in January 2023. NeuroSense is not obligated to sell any shares and the agreement may be terminated by either party or by mutual agreement. The Sales Agent will receive a 3% commission on gross proceeds and will be indemnified by NeuroSense, which will also reimburse certain expenses. The agreement includes customary representations, warranties, and conditions. This report, along with the full text of the Sales Agreement and the legal opinion of Goldfarb Gross Seligman & Co., is incorporated by reference into the company's existing registration statements.